Gilead Sciences, Inc.
NEWS
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
The World Health Organization (WHO) recommends against using Gilead Sciences’ remdesivir as a treatment for COVID-19.
Topline results from Gilead’s Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.
Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.
Remdesivir brought in $873 million in the third quarter, the first full quarter the drug has been on the market. But the drug is facing a storm of controversy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
JOBS
IN THE PRESS